Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous low-dose cyclophosphamide and prednisone for relapsed/refractory multiple myeloma with severe heart failure
ChiCTR-OPC-15007024Phase 4Recruiting
- Sponsor
- Shanghai Jing'an Zhabei Central Hospital
- Start
- Sep 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cyclophosphamide and prednisone in multiple myeloma (MM), sponsored by Shanghai Jing'an Zhabei Central Hospital. Primary endpoints: overall survival and progression-free survival. Started Sep 2014; status: recruiting.
02
Drugs
cyclophosphamideprednisone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR-OPC-15007024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15007024.